IONS Ionis Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IONS

Price (delayed)

$43.93

Market cap

$7.3B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.48

Enterprise value

$8.56B

?
Relative Growth: Rel. Growth: 11
Relative Strength: Rel. Strength: 7
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 24

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and ...

Highlights
IONS's quick ratio has soared by 157% year-on-year and by 141% since the previous quarter
The company's debt fell by 21% QoQ but it rose by 14% YoY
The net income has dropped by 111% year-on-year and by 73% since the previous quarter
Ionis Pharmaceuticals's EPS has shrunk by 98% YoY and by 73% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ionispharma.com

Key stats

What are the main financial stats of IONS

IONS stock price

How has the Ionis Pharmaceuticals stock price performed over time
Intraday
-3.98%
1 week
-2.03%
1 month
-26.46%
1 year
-29.79%
YTD
-44.47%
QTD
-44.6%

Financial performance

How have Ionis Pharmaceuticals's revenue and profit performed over time
Revenue
$874.09M
Gross profit
$858.07M
Operating income
-$594.36M
Net income
-$565.17M
Gross margin
98.2%
Net margin
-64.7%
The operating margin has dropped by 141% year-on-year and by 104% since the previous quarter
The company's net margin has shrunk by 128% YoY and by 109% QoQ
IONS's operating income has dropped by 123% year-on-year and by 69% since the previous quarter
The net income has dropped by 111% year-on-year and by 73% since the previous quarter

Price vs fundamentals

How does IONS's price correlate with its fundamentals

Growth

What is Ionis Pharmaceuticals's growth rate over time

Valuation

What is Ionis Pharmaceuticals stock price valuation
IONS P/E details
P/E
N/A
P/B
16.51
P/S
8.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.8
Ionis Pharmaceuticals's EPS has shrunk by 98% YoY and by 73% QoQ
The company's equity fell by 30% YoY and by 11% QoQ
The stock's price to book (P/B) is 30% less than its last 4 quarters average of 24.5 but 15% more than its 5-year quarterly average of 14.9
The P/S is 32% less than the last 4 quarters average of 12.7
IONS's revenue is down by 17% QoQ and by 7% YoY

Efficiency

How efficient is Ionis Pharmaceuticals business performance
Ionis Pharmaceuticals's return on sales has shrunk by 179% YoY and by 144% QoQ
IONS's return on equity has dropped by 144% year-on-year and by 89% since the previous quarter
Ionis Pharmaceuticals's ROIC has plunged by 132% YoY and by 90% from the previous quarter
IONS's return on assets has dropped by 93% year-on-year and by 72% since the previous quarter

Dividends

What is IONS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IONS.

Financial health

How did Ionis Pharmaceuticals financials performed over time
The total assets is 17% greater than the total liabilities
The current ratio has surged by 175% year-on-year and by 92% since the previous quarter
IONS's quick ratio has soared by 157% year-on-year and by 141% since the previous quarter
Ionis Pharmaceuticals's debt to equity has soared by 63% YoY but it has decreased by 12% from the previous quarter
The company's equity fell by 30% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.